Alaunos Therapeutics, Inc. (TCRT)
Oxford Ledge is still expanding full research coverage of TCRT. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A preclinical biopharmaceutical company developing oral small-molecule treatments for obesity through non-hormonal mechanisms.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-29
- 8-K Other material event; Financial statements and exhibits 2026-05-26
- 8-K Other material event; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K/A Amended annual report 2026-04-30
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for TCRT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open TCRT in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.